Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xtant Medical Holdings, Inc. (XTNT)
Price—Loading quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.5M | $90.0M | $59.3M | $35.3M | $33.1M | $33.0M | $30.1M | $15.4M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M | $34.4M | $42.5M | $43.5M | $50.1M | $62.3M | $39.1M | $22.3M | $18.9M | $22.6M | $21.0M | $12.1M |
| Gross margin | 62.92% | 58.17% | 60.75% | 55.44% | 58.79% | 64.48% | 65.73% | 60.23% | 60.72% | 69.21% | 65.86% | 63.11% | 57.11% | 68.66% | 69.79% | 78.18% |
| Research & development | $2.1M | $2.4M | $1.3M | $915,000 | $870,000 | $657,000 | $932,000 | $1.7M | $2.4M | $3.4M | $2.5M | $1.4M | $572,361 | — | — | — |
| Operating expenses | $77.0M | $80.3M | $65.6M | $38.9M | $36.3M | $35.1M | $44.8M | $103.6M | $87.9M | $69.8M | $51.2M | $28.6M | $27.9M | $27.6M | $27.5M | $20.7M |
| Operating income | $7.3M | −$12.1M | −$10.2M | −$6.8M | −$3.9M | −$751,000 | −$2.3M | −$60.1M | −$37.8M | −$7.5M | −$12.1M | −$6.3M | −$9.0M | −$4.9M | −$6.5M | −$8.6M |
| Operating margin | 5.44% | −10.30% | −11.13% | −11.65% | −6.97% | −1.41% | −3.48% | −83.21% | −45.85% | −8.38% | −20.35% | −17.73% | −27.24% | −14.99% | −21.39% | −55.87% |
| EBITDA | $12.5M | −$7.8M | −$7.0M | −$5.5M | −$2.5M | $1.3M | $890,000 | −$53.5M | −$29.4M | −$303,394 | −$7.2M | −$5.3M | −$8.3M | −$4.2M | −$5.7M | −$7.9M |
| EBITDA margin | 9.34% | −6.69% | −7.65% | −9.42% | −4.56% | 2.49% | 1.38% | −74.08% | −35.66% | −0.34% | −12.11% | −15.04% | −24.96% | −12.62% | −18.89% | −51.45% |
| Net income | $5.0M | −$16.4M | $660,000 | −$8.5M | −$4.8M | −$7.0M | −$8.2M | −$70.1M | −$52.4M | −$19.5M | −$2.2M | −$10.5M | −$12.7M | −$7.7M | −$3.0M | −$19.5M |
| Net profit margin | 3.71% | −14.03% | 0.72% | −14.64% | −8.77% | −13.17% | −12.71% | −97.09% | −63.52% | −21.66% | −3.66% | −29.74% | −38.38% | −23.39% | −9.97% | −126.27% |
| Basic EPSper basic share | $0.04 | -$0.12 | $0.01 | -$0.09 | -$0.06 | -$0.25 | -$0.63 | -$5.97 | -$34.76 | -$18.46 | -$0.24 | -$1.76 | -$2.80 | -$1.80 | -$0.80 | -$6.10 |
| Diluted EPSper diluted share | $0.03 | -$0.12 | $0.01 | -$0.09 | -$0.06 | -$0.25 | -$0.63 | -$5.97 | -$34.76 | -$18.46 | -$0.24 | -$1.76 | -$2.80 | -$1.80 | -$0.80 | -$6.10 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Harkey Wilmot B. / Mack Daniel / Nantahala Capital Management, LLC / Nantahala Capital Partners Limited Partnership | 68.39M |
Vizirgianakis Stavros G. | 7.52M |
Browne Sean E | 2.58M |
Beeson Jonn R. | 1.53M |
Brandt Kevin D | 943.74K |
BAKEWELL JOHN K | 914.12K |
Neils Scott C | 843.38K |
McNamara Robert | 754.15K |
Schallenberger Mark A. | 663.16K |
MITCHELL-KELLER LORI D | 353.12K |
Lipschultz Tyler | 158.23K |
JAIN ABHINAV | 158.23K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 10, 2025Form 4 | Orbimed ROF II LLC +1TenPercentOwner | SellCommon Stock · indirect | 17.11M | $0.42 | $7.19M | 0 |
| Apr 10, 2025Form 4 | Orbimed ROF II LLC +1TenPercentOwner | SellCommon Stock · indirect | 56.00M | $0.42 | $23.52M | 0 |